Yes they are talking approval. NP hit on this last time he

New Post Public Reply Private Reply Replies (3) Message Board
Riztheinvestor MoonShot303 #82032
590
Yes they are talking approval. NP hit on this last time he spoke. They will most likely file the BLA this summer.

NP said specifically during DrBeen show the other night that it would take six months for the FDA to get back to them on the BLA, bringing us to the end of the year. That’s not a surprise if people have been listing lately. THIS IS NOT NEW !! Personally I’ll just be happy if the BLA is good by the end of Q3. Not directed at you but let’s all just hope that it gets done within the next few months.

I personally thought this was a pretty decent CC and NP sounded pretty good today. I like how he had people speak for specific topics and everyone seemed very confident.

Also NASH is moving along very well and I personally look forward to this around Q4 for possible interim readout. I’m actually shocked that we are even on track for NASH. I believe Kelly is doing a good job with this. Anyone remember enrollment numbers vs the numbers needed ?

Another question.... What will it take for BTD for the cancer basket trial ? I’m not very up to speed on this, but Kelly was saying people in the trial were doing very well after several months and it seemed very promising.

TNBC I’m kinda wondering if enrollment slowed down due to no interest or we aren’t showing results ? Is COVID ‘slowing things down’, maybe cover story for we aren’t getting the results we wanted? I really don’t think that’s the case but I would like more answers on this.

Overall very good call.
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

NVIDIA Announces Details for Upcoming Q3 Financial Call

Updated Category News Views 84

NVIDIA's Conference Call for Third-Quarter Financial Results NVIDIA is preparing to host a conference call where the company's financial results for the third quarter will be addressed. This call is scheduled for Wednesday, November 20, at 2 p.m. PT, allowing both analysts and investors an opportunity to understand the company's performance in a detailed manner. Live...

Continue Reading
Endeavour Mining's Recent Share Buyback and Market Position

Updated Category News Views 165

Endeavour Mining Conducts Share Buyback Endeavour Mining plc, a leading gold producer, has recently undertaken a strategic initiative by purchasing its own shares in the market. This move signifies a strong commitment to enhancing shareholder value and reflects the company’s robust financial posture. Overview of the Shares Purchased The company acquired a total of...

Continue Reading
Embark on Luxurious Train Journeys Across China’s Landscapes

Updated Category News Views 116

Unveiling the Train of Glamour Experience Journey Beyond the Ordinary: The Train is The Destination Welcome aboard the Train of Glamour, a luxurious travel experience that redefines railway tourism in China. With an expanded route schedule in 2025, the Train of Glamour offers travelers a unique opportunity to explore breathtaking Chinese landscapes and diverse cultures....

Continue Reading
Important Alert for Flywire Investors Amid Legal Proceedings

Updated Category News Views 142

Critical Information for Flywire Corporation Investors If you have invested in Flywire Corporation (NASDAQ: FLYW) and experienced financial losses, it’s essential to pay attention to the upcoming deadline for a class action lawsuit. The Law Offices of Frank R. Cruz is reaching out to inform you of your rights regarding your investment losses and the ongoing litigation...

Continue Reading
Exploring Promising Biotech Stocks for Future Growth Opportunities

Updated Category News Views 94

Innovating in Biotechnology: A Bright Future Ahead The biotechnology sector is witnessing a remarkable transformation, largely fueled by advancements in artificial intelligence (AI). Companies are now leveraging machine learning to effectively identify drug targets, enhance molecular structures, and make accurate predictions regarding clinical trial outcomes. This...

Continue Reading